Peripheral Artery Disease Market to Witness Upsurge in Growth During the Forecast Period | Ixaka Ltd, Hemostemix, Caladrius Biosciences, Humacyte

Peripheral Artery Disease Market to Witness Upsurge in Growth During the Forecast Period | Ixaka Ltd, Hemostemix, Caladrius Biosciences, Humacyte
Peripheral Artery Disease Market
DelveInsight’s “Peripheral Artery Disease Market Insights, Epidemiology and Market Forecast– 2032” report delivers an in-depth understanding of the Peripheral Artery Disease, historical and forecasted epidemiology as well as the Peripheral Artery Disease market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

According to DelveInsight’s analysis, the Peripheral Artery Disease (PAD) market is projected to experience significant growth in the foreseeable future. This trajectory is attributed to the increasing prevalence of PAD across the 7 major markets (7MM), ongoing Research and Development (R&D) endeavors, the active involvement of leading pharmaceutical and biotechnology companies in this therapeutic area, and the anticipated introduction of emerging therapies.

In 2022, the market size of Peripheral Artery Disease was highest in the US among the 7MM accounting for approximately USD 4 billion, and lowest in Spain with USD 130 million which is further expected to increase by 2032.

The developing pipeline for Peripheral Artery Disease predominantly consists of cell therapies. Notable among these are Ixaka’s REX-001, Hemostemix’s ACP-01, Humacyte’s Human Acellular Vessel (HAV), and Caladrius Bioscience’s Honedra. These emerging therapies span various stages of development, including late-stage, mid-stage, and early-stage. Several of these promising treatments are poised to make their market debut in the near term.

DelveInsight’s “Peripheral Artery Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Peripheral Artery Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Peripheral Artery Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Peripheral Artery Disease Overview

Peripheral artery disease represents a prevalent manifestation of arterial narrowing in the upper and/or lower extremities, resulting in diminished blood flow. It’s widely recognized that PAD correlates with heightened morbidity and mortality in cardiovascular (CV) disease. In PAD, typically affecting the legs, insufficient blood supply fails to meet the body’s demand, leading to symptoms like leg pain during walking (claudication) and other associated discomforts.

While some individuals with PAD remain asymptomatic, the hallmark indication of lower-extremity PAD often manifests as painful muscle cramps in the hips, thighs, or calves during physical activity like walking, climbing stairs, or exercising. These discomforts, known as intermittent claudication, typically subside with rest. Symptoms of PAD tend to progress gradually over time. However, any sudden onset or exacerbation of symptoms may signal a serious issue necessitating prompt medical intervention.

Peripheral Artery Disease Market Key Facts

  • As per DelveInsight’s estimate, in 2021, there were 36,661,000+ cases of PAD in the 7MM. Approximately 55% of cases were reported in the US, compared to about 39% of cases in EU-5; Germany accounted for the highest number among EU-5 countries.

  • According to Alzamora et al. (2016), the occurrence of Peripheral Artery Disease is higher in men, especially < 65 years.

  • As per the assessment, Japan accounted for the lowest number of Peripheral Artery Disease cases among the 7MM.

  • The highest number of cases (approximately 61%) were diagnosed in the US, followed by EU-5 and Japan.

Peripheral Artery Disease Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Peripheral Artery Disease market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Peripheral Artery Disease market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Peripheral Artery Disease Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Peripheral Artery Disease Epidemiology Segmented by-

  • Total Prevalent Cases of PAD in the 7MM

  • Total Diagnosed Prevalent Cases of PAD in the 7MM

  • Severity-specific Prevalent Cases of PAD in the 7MM

  • Age-specific Prevalent Cases of PAD in the 7MM

  • Gender-specific Cases of PAD in the 7MM

  • Treatable Cases of PAD in the 7MM

Peripheral Artery Disease Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Peripheral Artery Disease market or expected to be launched during the study period. The analysis covers the Peripheral Artery Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Peripheral Artery Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Peripheral Artery Disease Market Will Evolve and Grow by 2032 @

Peripheral Artery Disease Therapeutics Analysis

As per DelveInsight’s assessment, with the increasing prevalent cases of Peripheral Artery Disease and the expected launch of upcoming therapies, the Peripheral Artery Disease market is anticipated to grow at an immense pace in the coming years.

Key Peripheral Artery Disease companies working in the peripheral artery disease market who are in different phases of developing therapies are – NovoNordisk, Takeda, Mercator MedSystems, Inc., Beijing Northland Biotech. Co., Ltd., Ixaka Ltd, Humacyte, Inc., CardioVascular BioTherapeutics, Proteon Therapeutics, ReNeuron Limited, Alucent Biomedical, Athersys, ARCA biopharma, Ambulero, Venturis Therapeutics and others.

The Leading Companies in the Peripheral Artery Disease Therapeutics Market Include:

  • Merck & Co., Inc

  • Aralez Pharmaceuticals

  • Legacy-Xspire Holdings

  • Janssen Pharmaceutical

  • Reven Pharmaceuticals, Inc.)

  • New Beta Innovation Limited

  • Mercator MedSystems

  • Ixaka Ltd (formerly known as Rexgenero)

  • Hemostemix

  • Caladrius Biosciences

  • Humacyte, Inc. 

  • And Many More

Peripheral Artery Disease Therapies Covered in the Report Include:

  • REX-001: Ixaka Ltd (formerly known as Rexgenero)

  • ACP-01: Hemostemix

  • SAKIGAKE designated Honedra (formerly known as CLBS12): Caladrius Biosciences

  • Human Acellular Vessel (HAV): Humacyte, Inc. 

  • RJX (Rejuveinix): Reven Pharmaceuticals, Inc.)

  • YQ23: New Beta Innovation Limited

  • Temsirolimus: Mercator MedSystems

  • And Many Others

Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Table of Content

1. Key Insights

2. Executive Summary 

3. Peripheral Artery Disease Competitive Intelligence Analysis

4. Peripheral Artery Disease Market Overview at a Glance

5. Peripheral Artery Disease Disease Background and Overview

6. Peripheral Artery Disease Patient Journey

7. Peripheral Artery Disease Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Peripheral Artery Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Peripheral Artery Disease Unmet Needs

10. Key Endpoints of Peripheral Artery Disease Treatment

11. Peripheral Artery Disease Marketed Products

12. Peripheral Artery Disease Emerging Drugs and Latest Therapeutic Advances

13. Peripheral Artery Disease Seven Major Market Analysis

14. Attribute Analysis

15. Peripheral Artery Disease Market Outlook (In US, EU5, and Japan)

16. Peripheral Artery Disease Access and Reimbursement Overview

17. KOL Views on the Peripheral Artery Disease Market

18. Peripheral Artery Disease Market Drivers

19. Peripheral Artery Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States